Companies across Hong Kong's diverse sectors are reshaping their operational strategies through aggressive capital market maneuvers and AI integrations. Institutional investors are beginning to reassess the underlying fundamentals of these mid-cap assets, as persistent stock buybacks and technology-driven efficiency gains become central to the current earnings cycle, according to people familiar with the matter.

Cao Cao Mobility (2643.HK)

Mobility provider Cao Cao Mobility has continued to signal capital confidence to the market. The company has executed 12 rounds of share repurchases so far in 2026, deploying roughly HKD 94.58M, according to exchange filings. Meanwhile, the firm is targeting the commercialization of autonomous driving, with executives recently outlining scalability paths for Robotaxi operations at the World Artificial Intelligence Conference, seeking new margin drivers in a highly competitive market.

METiS Therapeutics (7666.HK)

Shares of this AI-driven nanomaterials company have rebounded significantly following a major cross-border technology transaction. METiS Therapeutics secured a global exclusive licensing agreement with Boulevard for MTS-128, which is expected to bring in an upfront payment of USD 20M and potential milestone payouts up to USD 1.6B. Analysts noted that the research efficiency of its AI platform in life sciences is rapidly materializing.

Microware Group (1985.HK) & i-Control Holdings (1402.HK)

Enterprise IT infrastructure providers are showing notable earnings recoveries. Microware Group (1985.HK) reported an annual net profit of HKD 30.2M for the fiscal year ended March 2026, marking a 2.7-fold increase year-over-year. The company expected to deepen its AI research and recently raised around HKD 99.2M through a share placement to boost liquidity. Similarly, multimedia solutions provider i-Control Holdings (1402.HK) turned a profit, recording revenue of HKD 105M and a net income of HKD 367,000 for the same period.

GF Securities (1776.HK) & JW Therapeutics (2126.HK)

Industry leaders in varied cycles are fine-tuning their strategic postures. GF Securities (1776.HK) recently launched a new AI-powered platform aimed at rebuilding the institutional client experience, while adjusting its margin lending cap to 2.5 times its net capital. Separately, JW Therapeutics (2126.HK) saw an uptick recently, buoyed by the broader biotech sector's global expansion narrative; despite enduring multiple executive turnovers over the past 15 months, the supplementary application for its core cell therapy product has been accepted.

OKG Technology Holdings (1499.HK) and Other Key Movements

Other entities are navigating deep operational reshuffles. Web3-focused OKG Technology Holdings (1499.HK) terminated its digital asset business, posting a revenue of HKD 192M for the fiscal year ending March, alongside widened net losses. Packaging manufacturer Zheng Ye International (3363.HK) finalized a CEO transition in late June amid shrinking appliance orders. In the passive investment space, the AI-tracking ChinaAMC HK-US AI ETF (3140.HK) officially listed in March and joined the designated short-selling list, while the covered call ETF Global X S&P 500 Covered Call ETF (3415.HK) optimized its trading structure by reducing its lot size to 25 shares.

This article does not constitute investment advice.